论文部分内容阅读
将80例口服降糖药物血糖控制不佳的2型糖尿病患者随机分为重和林M30组(治疗组)和诺和锐30组(对照组),每组40例。对照组患者应用诺和锐30,治疗组患者应用重和林M30,采用每日早晚皮下注射的方案,治疗12周后观察其降糖效果和安全性。结果:两组之间的空腹血糖(FPG)、餐后2小时血糖(2h PG)、糖化血红蛋白、胰岛素用量、低血糖发生例数均无显著性差异(P>0.05),结论:重和林M30对于口服降糖药物控制不佳的2型糖尿病患者可以有效的控制血糖,低血糖发生率低,安全性好,和胰岛素类似物诺和锐30无明显差异。
Eighty patients with type 2 diabetes who were poorly controlled by oral hypoglycemic drugs were randomly assigned to Chonghelin M30 group (treatment group) and Novo-Rui 30 group (control group), 40 cases in each group. Control group of patients with Novo Rui 30, the treatment group patients with heavy and forest M30, using daily morning and evening subcutaneous injection of the program, after 12 weeks of treatment to observe the hypoglycemic effect and safety. Results: There was no significant difference in fasting blood glucose (FPG), 2h PG, HbA1c, insulin dosage and incidence of hypoglycemia between the two groups (P> 0.05). Conclusion: M30 can effectively control blood sugar in patients with type 2 diabetes who are not controlled by oral hypoglycemic drugs. The incidence of hypoglycemia is low and the safety is good. M30 has no significant difference with insulin analogue NovoRui 30.